NCT02583542

A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers

A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 118 (estimated)
• Sponsor: Queen Mary University of London · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Open-label, multicentre phase Ib/IIa study of AZD2014 administered with selumetinib. There are two parts to this study: a dose-escalation part in treatment-refractory advanced solid tumours and a subsequent separate expansion cohort part for TNBC, squamous cell lung cancers, non-squamous cell lung cancers with KRAS mutations and non-squamous cell lung cancers with wild-type KRAS

Conditions

• Triple-Negative Breast Cancer
• Squamous Cell Lung Cancer
• Non-squamous Cell Lung Cancer With KRAS Mutations
• Non-squamous Cell Lung Cancer With Wild-type KRAS

Interventions

Type	Name	Description
DRUG	AZD2014	AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
DRUG	AZD6244	Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.

Timeline

• Start date: 2015-06-01
• Primary completion: 2020-03-01
• Completion: 2020-03-01
• First posted: 2015-10-22
• Last updated: 2020-02-25

Locations

4 sites across 1 country: United Kingdom